RYTM RHYTHM PHARMACEUTICALS INC revenue, earnings and financials

For the quarter ended June 30, 2026, RHYTHM PHARMACEUTICALS INC reported revenue of $71.3M (up 46.9% from a year earlier), net income of −$49.3M and diluted EPS of −$0.73; over the last four quarters revenue was $240M and net income −$9.00M; for the fiscal year ended December 2025 revenue was $190M, up 45.8% on the year before.

RYTM annual revenue and earnings

• Fiscal year ended Dec 2025: revenue $190M, gross profit n/a, operating income −$192M, net income −$197K (margin -0.1%), EPS −$3.11
• Fiscal year ended Dec 2024: revenue $130M, gross profit n/a, operating income −$266M, net income −$261K (margin -0.2%), EPS −$4.34
• Fiscal year ended Dec 2023: revenue $77.4M, gross profit n/a, operating income −$184M, net income −$185K (margin -0.2%), EPS −$3.20
• Fiscal year ended Dec 2022: revenue $23.6M, gross profit n/a, operating income −$179M, net income −$181K (margin -0.8%), EPS −$3.47
• Fiscal year ended Dec 2021: revenue $3.15M, gross profit n/a, operating income −$170M, net income −$69.6K (margin -2.2%), EPS −$1.40

RYTM quarterly revenue and earnings

• Quarter ended Jun 30, 2026: revenue $71.3M (up 46.9% year over year), net income −$49.3M, EPS −$0.73
• Quarter ended Mar 31, 2026: revenue $60.1M (up 83.8% year over year), net income −$55.6M, EPS −$0.83
• Quarter ended Dec 31, 2025 (from the annual report): revenue $57.3M (up 36.9% year over year), net income $149M, EPS −$0.73
• Quarter ended Sep 30, 2025: revenue $51.3M (up 54.3% year over year), net income −$52.9M, EPS −$0.82
• Quarter ended Jun 30, 2025: revenue $48.5M (up 66.8% year over year), net income −$46.6M, EPS −$0.75
• Quarter ended Mar 31, 2025: revenue $32.7M (up 25.9% year over year), net income −$49.5M, EPS −$0.81
• Quarter ended Dec 31, 2024 (from the annual report): revenue $41.8M (up 72.6% year over year), net income $217M, EPS −$0.71
• Quarter ended Sep 30, 2024: revenue $33.3M (up 47.8% year over year), net income −$43.6M, EPS −$0.73
• Quarter ended Jun 30, 2024: revenue $29.1M (up 51.3% year over year), net income −$32.3M, EPS −$0.55
• Quarter ended Mar 31, 2024: revenue $26.0M (up 126.4% year over year), net income −$141M, EPS −$2.35
• Quarter ended Dec 31, 2023 (from the annual report): revenue $24.2M (up 175.7% year over year), net income $143M, EPS −$0.70
• Quarter ended Sep 30, 2023: revenue $22.5M (up 425.3% year over year), net income −$44.2M, EPS −$0.76
• Quarter ended Jun 30, 2023: revenue $19.2M (up 112.0% year over year), net income −$46.7M, EPS −$0.82
• Quarter ended Mar 31, 2023: revenue $11.5M (up 665.6% year over year), net income −$52.2M, EPS −$0.92
• Quarter ended Dec 31, 2022 (from the annual report): revenue $8.79M (up 383.8% year over year), net income $138M, EPS −$0.74
• Quarter ended Sep 30, 2022: revenue $4.28M (up 316.7% year over year), net income −$40.9M, EPS −$0.79
• Quarter ended Jun 30, 2022: revenue $9.07M (up 3208.8% year over year), net income −$45.0M, EPS −$0.89
• Quarter ended Mar 31, 2022: revenue $1.50M (up 4180.0% year over year), net income −$52.8M, EPS −$1.05
• Quarter ended Dec 31, 2021 (from the annual report): revenue $1.82M, net income $26.7M, EPS −$0.90
• Quarter ended Sep 30, 2021: revenue $1.03M, net income −$35.1M, EPS −$0.70

RYTM cash flow, buybacks and dividends

• Fiscal year ended Dec 2025: operating cash flow −$116M, share buybacks n/a
• Fiscal year ended Dec 2024: operating cash flow −$114M, share buybacks n/a
• Fiscal year ended Dec 2023: operating cash flow −$136M, share buybacks n/a
• Fiscal year ended Dec 2022: operating cash flow −$173M, share buybacks n/a
• Fiscal year ended Dec 2021: operating cash flow −$146M, share buybacks n/a

RYTM balance sheet

• Jun 30, 2026: cash $65.6M, total assets $437M, total liabilities $220M, shareholders' equity $103M, long-term debt $93.4M
• Mar 31, 2026: cash $62.1M, total assets $442M, total liabilities $205M, shareholders' equity $123M, long-term debt $98.3M
• Dec 31, 2025: cash $54.3M, total assets $480M, total liabilities $210M, shareholders' equity $139M, long-term debt $101M
• Sep 30, 2025: cash $52.1M, total assets $507M, total liabilities $211M, shareholders' equity $149M, long-term debt $103M
• Jun 30, 2025: cash $136M, total assets $373M, total liabilities $239M, shareholders' equity −$11.9M, long-term debt $106M
• Mar 31, 2025: cash $106M, total assets $387M, total liabilities $224M, shareholders' equity $18.9M, long-term debt $108M
• Dec 31, 2024: cash $89.1M, total assets $392M, total liabilities $228M, shareholders' equity $21.7M, long-term debt $108M
• Sep 30, 2024: cash $47.5M, total assets $364M, total liabilities $211M, shareholders' equity $11.2M

What is RYTM's revenue?

RHYTHM PHARMACEUTICALS INC reported $240M of revenue over its last four quarters, through June 30, 2026.

Is RYTM profitable?

No. RHYTHM PHARMACEUTICALS INC lost $9.00M over the last four quarters.

What is RYTM's EPS?

Diluted earnings per share over the last four quarters were −$3.11; −$0.73 in the latest quarter.

RYTM ownership and insider trades · All stocks